Search academic texts

Information × Registration Number 0216U001141, 0115U000813 , R & D reports Title To improve the treatment of patients with non-Hodgkin diffuse large-B-lymphoma considering immunohistohimichnyh and molecular genetic markers popup.stage_title Head Kryachok Iryna, Registration Date 25-01-2016 Organization Ukrainian Research Institute of Oncology and Radiology popup.description2 Object of study - non-Hodgkin lymphomas, immunohistochemical and molecular-genetic factors of the disease. Objective of study - to determine the role of immunohistochemical and molecular genetic markers in the prognosis of diffuse large B-cell lymphoma, to optimize treatment of patients with diffuse large B-cell lymphoma with novel treatment approaches. Methods and apparatus : morphological, immunohistochemical, clinical, statistical, ultrasound apparatus "Aloca", CT. During the reporting period, the analysis of the treatment of 86 patients with diffuse large B-cell lymphoma (DLBCL). According to immunohistochemical algorithm Hans et al patients were divided into two groups: germinal center B-cell–like (GCB) and not otherwise specified DLBCL (NOS). DLBCL(GCB) is characterized with positive expression of BCL6, BCL2 and CD30, when for DLBCL (NOS) MUM1 and CD10 are positive (р<0,05). Better progression-free survival rate (PFS) was observed in patients with GCB subtype and positive expression of CD10 (р>0,05). The number of deaths and relapses was significantly greater in ALC/AMC<1,77 (80 % vs 0 %, р<0,05) group. A313A genotype significantly associated with an increased risk of relapse inpatients compared to A313G genotypes or G313G (62.1 % vs. 37.8%, p = 0.01). 5 - year PFS in patients who were homozygous for GSTP1 genotype A313A was lower than in patients with genotype A313G or G313G ( 43% vs. 55%, p = 0.02 ; criteria Cox F = 2.2). 5-year overall survival (OS) in patients with genotypes G313G or A313G was higher than in patients with homozygous genotype for A313A GSTP1 ( 75 % vs. 58%, p = 0.02 ; criteria Cox F = 2,7). A study of PD-L1 expression in 15 patients with DLBCL was provided. If a patient has a high level of expression of the marker ligand indices of general and disease-free survival is significantly lower in comparison with the low and / or absent expression of PD-L1 ( p = 0.001 ). Treatment protocols for patients with DLBCL in high-risk group were developed and protocols for patients with primary mediastinal lymphoma with new treatment scheme – R-Da-EPOCH. An analysis of the immediate results of complex treatment of 31 patients with primary mediastinal large B cell lymphoma (PMBL) was provided. Overall response rate (ORR) in the study group was 100 %. Complete response (CR) was achieved in 15 patients (65.2%), partial (PR) - in 8 patients (34.8 %). Treatment was accompanied by moderate hematological and non-hematological toxicity. Grade 4 anemia was observed in 8.6%. Febrile neutropenia was observed in 4.3% of patients. Areas of application - oncology Product Description popup.authors Є. Кущевий К. Філоненко Крячок Ірина Анатоліївна О. Алексик Титоренко Ірина Борисівна popup.nrat_date 2020-04-02 Close